ArticleMolecular biology reports2025
Enhanced pro-apoptotic and pro-oxidative effects of hesperidin on LNCaP prostate cancer cell line through nano-emulsification.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using natural substances as adjuvant cancer therapy can help improve the condition of patients undergoing cancer treatment. Despite the fewer side effects of bioactive molecules, these substances still face many challenges. Nanotechnology can partially overcome these obstacles and increase the effectiveness of natural compounds many times over. Therefore, this research examined and contrasted the impact of hesperidin nanoemulsions (HES-NE) and free hesperidin (HES), with a significant focus on cell death pathways in (PCa) cells. qRT-PCR analysis revealed increased expression of the apoptotic genes P53 and Bax, and reduced expression of the anti-apoptotic gene Bcl-2, in cells treated with HES-NE. Caspase-3 enzyme activity assay indicated increased apoptosis in LNCaP cells treated with HES-NE. Furthermore, assessment of oxidative stress biomarkers revealed a dose-dependent increase in ROS and malondialdehyde (MDA) generation, and a decrease in superoxide dismutase (SOD) and glutathione peroxidase (GHS-Px) levels upon treatment with HES-NE. Our findings revealed that nanoformulated HES significantly enhanced its ability to induce apoptosis in PCa cells through P53/Bax/Bcl-2-mediated signaling pathways, compared to its free form.
Indexed as
Identifiers
41032207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.